Show
Sort by
-
Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)
-
Long-term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) With Relapsed/Refractory (r/r) Follicular Lymphoma (FL) Treated With Tisagenlecleucel in the ELARA Trial
-
Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and >= 2 prior lines of therapy : key results of the phase-II expansion
(2022) ONCOLOGY RESEARCH AND TREATMENT. In Oncology Research and Treatment 45(Supplement 2). p.50-51 -
Nivolumab in combination with gemcitabine and oxaliplatin (GemOx) in relapse/refractory T-cell lymphoma : preliminary results of the experimental arm of the NIVEAU trial
(2021) ONCOLOGY RESEARCH AND TREATMENT. In Oncology Research and Treatment 44(supplement 2). p.128-129 -
Glofitamab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) : durable complete responses and manageable safety observed at clinically relevant doses in Phase I dose escalation
(2020) ONCOLOGY RESEARCH AND TREATMENT. In Oncology Research and Treatment 43(Supplement 4). p.58-59 -
A randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (Suniforecast)
-
Phase 3 study of ibrutinib as first-line treatment in older patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) : a 4-year follow-up from the RESONATE-2 study
-
International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM))
-
Anakoinosis: communicative reprogramming of tumor systems: for rescuing chemorefractory neoplasia